Bioimpacts最新文献

{"title":"Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate.","authors":"Imran Anwar, Nadiah Zafar, Asif Mahmood, Zulcaif, Riffat Latif","doi":"10.34172/bi.30257","DOIUrl":"10.34172/bi.30257","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Microneedle patch is one of the fascinating drug delivery approaches that offers low invasiveness and a painless physical application to enhance the delivery of micro and macro-molecules into the skin.</p><p><strong>Methods: </strong>Variable contents of chitosan and polyvinyl alcohol were used for the development of doxazosin mesylate containing sustained release microneedle patches via solvent casting technique. The prepared patches were evaluated for microscopic evaluation, mechanical strength, drug loading (%) and Fourier transform infrared spectroscopy (FTIR) etc. The skin penetration study was performed by using pig ear skin and results were captured through confocal microscopy. <i>Ex-vivo</i> release study and pharmacokinetic evaluation were also performed.</p><p><strong>Results: </strong>Sharp needle tips with a height of 600µm and a base of 200µm were confirmed through microscopic examination. Optimized formulation (SRF-6) exhibited loading of 92.11% doxazosin mesylate with appreciable strength up to 1.94N force. <i>Ex-vivo</i> release studies revealed 87.24% release within 48 hours. Moreover, the pharmacokinetic parameters in case of optimized patch formulation (SRF-6) were markedly improved i.e. MRT (19.46 h), AUC (57.12 μg.h /mL), C_max (2.16 µg /mL), t_max (10.10 h) and t_1/2 (6.32 h) as compared to commercially available tablet. Biocompatibility of the developed patches was validated from skin irritation studies.</p><p><strong>Conclusion: </strong>Results confirmed the successful fabrication of microneedle patch having sufficient strength and effective penetration ability into the skin to ensure controlled release of incorporated drug for the intended duration. It can be employed as an efficient carrier system for other therapeutics those are prone to bioavailability issues due to first pass effect after their oral administration.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30257"},"PeriodicalIF":2.2,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular dynamics simulation in tissue engineering.","authors":"Ali Rahmani, Rahim Jafari, Samad Nadri","doi":"10.34172/bi.30160","DOIUrl":"10.34172/bi.30160","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>In tissue engineering, the interaction among three primary elements, namely cells, material scaffolds, and stimuli, plays a pivotal role in determining the fate of cells and the formation of new tissue. Understanding the characteristics of these components and their interplay through various methodologies can significantly enhance the efficiency of the designed tissue engineering system. In silico methods, such as molecular dynamics (MD) simulation, use mathematical calculations to investigate molecular properties and can overcome the limitations of laboratory methods in delivering adequate molecular-level information.</p><p><strong>Methods: </strong>The studies that used molecular dynamics simulation, either alone or in combination with other techniques, have been reviewed in this paper.</p><p><strong>Results: </strong>The review explores the use of molecular dynamics simulations in studying substrate formation mechanism and its optimization. It highlights MD simulations' role in predicting biomolecule binding strength, understanding substrate properties' impact on biological activity, and factors influencing cell attachment and proliferation. Despite limited studies, MD simulations are considered a reliable tool for identifying ideal substrates for cell proliferation. The review also touches on MD simulations' contribution to cell differentiation studies, emphasizing their role in designing engineered extracellular matrix for desired cell fates.</p><p><strong>Conclusion: </strong>Molecular dynamics simulation as a non-laboratory tool has many capabilities in providing basic and practical information about the behavior of the molecular components of the cell as well as the interaction of the cell and its components with the surrounding environment. Using this information along with other information obtained from laboratory tools can ultimately lead to the advancement of tissue engineering through the development of more appropriate and efficient methods.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30160"},"PeriodicalIF":2.2,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A potential mechanism for tau protein modulating in schizophrenia with transcranial direct current stimulation intervention: A randomized controlled trial.","authors":"Ali Reza Shafiee-Kandjani, Farnaz Chalabianloo, Sara Farhang, Dariush Shanehbandi, Behzad Shalchi","doi":"10.34172/bi.30274","DOIUrl":"10.34172/bi.30274","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Schizophrenia involves cognitive deficits, including working memory impairments. Researches indicate tau protein abnormalities may contribute to cognitive dysfunction in schizophrenia. While transcranial direct current stimulation (tDCS) shows promise in improving cognitive function, its effects on tau protein and working memory in schizophrenia remain unclear.</p><p><strong>Methods: </strong>Forty participants were randomly assigned to receive either tDCS or sham treatment in this randomized clinical trial. The tDCS group received anodal stimulation over the left dorsolateral prefrontal cortex (DLPFC) for 20 minutes, while the sham group received a placebo. Serum tau levels and working memory were assessed before and after using ELISA and the digit span task.</p><p><strong>Results: </strong>The results showed that the tDCS group had a significantly higher increase in phosphorylated tau protein serum levels compared to the sham group (5.53 ± 3.67 vs. 1.49 ± 3.90, <i>P</i> < 0.05). There was no significant mean change difference in serum levels of total tau protein between the groups. Females displayed higher increase in both total tau (1.88 ± 0.66 vs. 1.43 ± 0.80, <i>P</i> = 0.664) and p-tau levels (4.92 ± 0.88 vs. 2.11 ± 0.64, <i>P </i>= 0.014). The tDCS group also showed significantly higher improvement in working memory than the sham group (<i>P </i>< 0.05). Correlations between tau changes and memory enhancements approached significance (r_{(total tau)} = 0.30; <i>P </i>= 0.051, r_(p-tau) = 0.27; <i>P </i>= 0.063).</p><p><strong>Conclusion: </strong>These findings reveal the tDCS impact on tau markers, shedding light on the disorder's molecular pathways and sex influences. Enhanced memory, linked to tau changes, suggests its potential as a treatment indicator.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30274"},"PeriodicalIF":2.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in nanocarrier-mediated delivery of chrysin: Enhancing solubility, bioavailability, and anticancer efficacy.","authors":"Sheida Dabiri, Sevda Jafari, Ommoleila Molavi","doi":"10.34172/bi.30269","DOIUrl":"10.34172/bi.30269","url":null,"abstract":"<p><p>Chrysin, a natural phytochemical compound found in various plant sources, possesses diverse pharmacological benefits, including anticancer, antioxidant, antidiabetic, neuroprotective, cardioprotective, hepatoprotective, immunoregulatory, and anti-inflammatory properties. Despite its well-documented biological activities, chrysin's low water solubility and bioavailability hinder its clinical development. This review explores the application of nanocarriers as a strategic approach to overcome these challenges and enhance the delivery of chrysin. Nanocarriers, including polymer-based nanoparticles (NPs), lipid-based NPs, and inorganic nanocarriers, have shown promise in improving the solubility, bioavailability, and tumor-targeted delivery of chrysin. The paper discusses chrysin's anticancer effects on different types of human cancers, elucidating its impact on crucial signaling pathways involved in tumorigenesis. The review categorizes and analyzes various nanocarriers, providing insights into their structural properties and drug release profiles. Among the nanocarriers, polymer-based NPs, especially those utilizing PLGA, emerge as promising strategies for chrysin encapsulation, demonstrating improvements in drug release, stability, and bioavailability. Lipid-based NPs and inorganic nanocarriers also exhibit potential in enhancing chrysin delivery. The comprehensive insights provided contribute to a deeper understanding of chrysin's pharmacological properties and its potential clinical applications, offering valuable perspectives for future research and translation into clinical settings. The review underscores the importance of selecting suitable structures for chrysin encapsulation to enhance its physicochemical properties and anticancer effects, paving the way for innovative nanomedicine approaches in cancer therapy.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30269"},"PeriodicalIF":2.2,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation and evaluation of lipid-based sustained release pellets of chlorpheniramine maleate by the wet extrusion-spheronization method.","authors":"Mohammadreza Abbaspour, Asieh Sadooghi, Elham Khodaverdi, Hossein Shahdadi Sardou, Ali Nokhodchi","doi":"10.34172/bi.30098","DOIUrl":"10.34172/bi.30098","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>This study aimed to investigate the feasibility of preparation of sustained-release chlorpheniramine maleate (CPM) pellets based on Compritol® as a lipid matrix and evaluation of the affecting factors on pellet properties.</p><p><strong>Methods: </strong>Using the D-optimal experimental design, different pellet formulations containing various amounts of CPM, Compritol® and Avicel were prepared by the wet extrusion-spheronization method. Then the pellets were cured at 40, 65 and 90 °C for 4 and 8 h to study the effect of the thermal process. The physicomechanical properties of the pellets were investigated in terms of particle size distribution, pelletization yield, mechanical strength, aspect ratio and sphericity. To investigate the possible interaction of CPM and Compritol®, as well as to evaluate the morphology and surface characteristics of the pellets DSC and SEM were used, respectively. Also, to investigate the drug release rate from pellets the dissolution test was carried out and mean dissolution time (MDT) was calculated to compare different formulations.</p><p><strong>Results: </strong>The results showed that the curing process up to 65 °C improves the strength of the pellets. However, increasing the curing temperature from 65 to 90 °C and also increasing the curing time from 4 to 8 h did not have a significant effect on the strength of the pellets but increased the drug release rate of pellets. Increasing the amount of the drug or decreasing Compritol® in the matrix of pellets leads to a larger particle size with greater mechanical strength. All formulations of the pellets had an aspect ratio and sphericity of about 1.1 and 0.9 respectively, which indicates the spherical shape of the pellets as shown by SEM. DSC thermograms indicate the reduction of the crystallinity or the change of the crystalline form of the drug to amorphous during the pelletization process.</p><p><strong>Conclusion: </strong>The results revealed the feasibility of preparing lipid-based sustained-release matrix pellets using the wet extrusion-spheronization method. The optimal formulation in terms of physicomechanical properties and release rate was the formulation containing 8% CPM, 67% Compritol® and 25% Avicel, which were dried at 40 ° C for 4 h and released about 90% of the drug within 12 h.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30098"},"PeriodicalIF":2.2,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Material synthesis and design optimization of biomaterials for biomedical implant applications.","authors":"Nilesh Tipan, Ajay Pandey, Pushyamitra Mishra","doi":"10.34172/bi.30010","DOIUrl":"10.34172/bi.30010","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>In the modern era, the use of biomaterials in orthopaedics has revolutionised the healthcare sector. Traditionally, some non-biodegradable materials such as titanium and stainless steel are used as biomaterials. However, issues such as toxicity, poor tissue adhesion, and stress-shielding effect can occur with non-biodegradable materials for bone fracture fixation. Several biodegradable materials have been developed to resolve these issues but have not yet been appropriately industrialized for implant applications. These substances can be classified into metals, ceramics, and polymers, which can be blended to create composites that enhance biocompatibility and biomechanical characteristics.</p><p><strong>Methods: </strong>This study began by contrasting the biocompatibility and mechanical compatibility among various alloys: biodegradable low entropy (BLE) alloys, biodegradable medium entropy (BME) alloys, biodegradable high entropy (BHE) alloys, and non-biodegradable medium entropy (NBME) alloys. Additionally, the design morphology of bio-implants like plates, screws, and others was inspected. Moreover, a meta-analysis was conducted to optimize the design of biomaterials, ensuring appropriate biocompatibility and degradation rate. A subsequent statistical analysis was executed to determine the optimal material concentration for bio-implant alloy creation.</p><p><strong>Results: </strong>Initially, in this paper, the advantages of biodegradable materials over conventional non-biodegradable materials are discussed and bibliometric analysis is done to show recent research contributions in the field of biomedical implant application. Then compared biocompatibility and mechanical compatibility among BLE alloys, BME alloys, BHE alloys, NBME alloys. Furthermore, investigated the design morphology of bio-implants such as plates and screws. Also presented a meta-analysis for design optimization of biomaterials to meet suitable biocompatibility and biodegradation rates and presented a statistical analysis among them, which helps to select the appropriate material concentration for bio-implant alloy formation.</p><p><strong>Conclusion: </strong>It was observed that in biodegradable materials, tensile strength is in the pattern of NBME > BHE > BME > BLE, and the degradation rate is in the pattern of BME > NBME > BHE > BLE. This study suggests that biodegradable materials (BLE and BME) are a much better choice than non-biodegradable materials in orthopaedic applications. It was also observed that a Biodegradable locking compression plate (BLCP) can provide the necessary strength and performance. Further, the systematic meta-analysis presented herein furnishes crucial data to researchers, guiding them in enhancing the efficiency of diverse biomaterials and optimizing their designs.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30010"},"PeriodicalIF":2.2,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A procedure for DNA methylation assessment in osteoporosis-related gene promoters of umbilical cord blood: A study on the Prospective Epidemiological Research Studies in Iran (PERSIAN) birth cohort.","authors":"Sadegh Baradaran Mahdavi, Seyed Morteza Javadirad, Mahsa Rafieian, Parnian Poursafa, Vajihe Azimian Zavareh, Seyede Shahrbanoo Daniali, Motahar Heidari-Beni, Masoomeh Goodarzi-Khoigani, Babak Vahdatpour, Hossein Mirhendi, Roya Kelishadi","doi":"10.34172/bi.30095","DOIUrl":"10.34172/bi.30095","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>It is believed that DNA methylation can modify disease susceptibility in response to environmental factors as early as the perinatal period. In this study, we aimed to present a streamlined DNA methylation analysis procedure for osteoporosis-related gene promoters in the umbilical cord blood.</p><p><strong>Methods: </strong>The Prospective Epidemiological Research Studies in Iran (PERSIAN) birth cohort was established in 2016. In this study, a total of 300 umbilical cord blood samples were collected at the time of delivery. For all samples, DNA was extracted and converted using sodium bisulfite. Multiple primer sets were designed for <i>Wnt1, Wnt10b</i>, β-catenin, <i>OPG</i>, and <i>RANKL</i> gene promoters in the online MethPrimer platform. Next, bisulfite sequencing PCR (BSP), as the gold standard method for exploring methylated and unmethylated cytosines, was performed in a gradient-controlled setting. The PCR products were then purified and directly sequenced. Subsequently, the chromatograms were interpreted.</p><p><strong>Results: </strong>For <i>Wnt10b</i>, β-catenin, and <i>OPG</i> genes, the converted DNA could be successfully amplified. The frequency of acceptable chromatograms for analysis was 195 for <i>Wnt10b</i> (195/300, 0.65%), 198 for β-catenin (198/300, 0.66%), and 50 for <i>OPG</i> (50/50, 100%).</p><p><strong>Conclusion: </strong>BSP can be efficiently used to investigate the methylation of target gene promoters in umbilical cord blood DNA.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30095"},"PeriodicalIF":2.2,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of protein N linear epitopes in serodiagnosis of COVID-19 infection.","authors":"Sahar Farajnia, Nazli Khajenasiri, Safar Farajnia, Farzin Seyrafi, Nasim Bakhtiyari","doi":"10.34172/bi.30232","DOIUrl":"10.34172/bi.30232","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Despite the efforts to contain the spread of COVID-19, the virus remains in circulation, posing a considerable risk to populations across the globe. Hence, rapid and early detection of this infection is essential for effective disease control. The nucleocapsid (N) protein of the virus serves as a primary target for antibody response during CoV2 infections, making it a potential candidate for COVID-19 detection. This study aims to prepare and evaluate the linear epitopes of the N protein for serodiagnosis of COVID-19 infection.</p><p><strong>Methods: </strong>The linear epitope of the N protein gene was identified using ABCpred, BCpred, and IEDB. These epitopes were subsequently amplified by RT-PCR, cloned, and expressed in soluble form in the <i>E. coli</i> BL21 strain. The recombinant protein was purified using the Ni-NTA column. The reactivity of purified N protein with sera from SARS-CoV-2 patients was analyzed using an ELISA assay.</p><p><strong>Results: </strong>Sequencing analysis demonstrated the successful cloning of the linear epitopes of the N protein into the PET-28a vector, along with an n-terminal His-tag fusion. The recombinant protein was produced in <i>E. coli</i> BL21 and purified with a Ni-NTA column. The analysis demonstrated that the N protein linear epitopes were expressed in a soluble form and appeared as a 50 kDa band in the SDS-PAGE. Examination for the reactivity of the purified N protein with the COVID-19 patient's sera by ELISA revealed that the N protein recognizes the infection with high sensitivity and specificity.</p><p><strong>Conclusion: </strong>The results of this study indicated that linear epitopes of the SARS-CoV-2 N protein are highly immunogenic and could be exploited for serodiagnosis of infection in patients suspected of COVID-19 infection.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30232"},"PeriodicalIF":2.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial.","authors":"Hamideh Abbaspour Kasgari, Siavash Moradi, Ahmad Alikhani, Nasim Ahmadian","doi":"10.34172/bi.29952","DOIUrl":"10.34172/bi.29952","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Drug repurposing as a low-cost, time-saving, and often less risky strategy has been attractive for the treatment of coronavirus disease 2019 (COVID-19) during the pandemic. This trial aimed to evaluate the effectiveness of dolutegravir, an HIV-1 integrase inhibitor, in admitted patients with moderate COVID-19.</p><p><strong>Methods: </strong>This study was a randomized, double-blind, placebo-controlled clinical trial assessing the efficacy of dolutegravir in adults admitted to a hospital in Ghaemshahr, Mazandaran Province, Iran. Patients aged 18-80 years with early symptoms of moderate COVID-19, which was confirmed based on reverse transcription polymerase chain reaction (RT-PCR) and/or chest computed tomography (CT) scan, were considered to be included in this study. Patients were randomly assigned in a 1:1 ratio to receive 50 mg dolutegravir plus the standard treatment regimen or the same value of placebo plus the standard treatment regimen, daily for 7 days. The standard treatment regimen was remdesivir 200 mg on day 1 followed by 100 mg for five days or until discharge. The primary endpoint was recovery 10 days after the beginning of the study.</p><p><strong>Results: </strong>Between August 22 and October 23, 2021, of 120 patients who were enrolled, 93 patients were randomly assigned to receive 50 mg dolutegravir (n=46) or the placebo regimen (n=47). No significant difference was observed between the two intervention groups based on the obtained results including frequency of respiratory modes during the first five days of admission, respiratory rate, and O₂ saturation during six time periods.</p><p><strong>Conclusion: </strong>The results showed that in adult patients admitted to the hospital with moderate COVID-19, treatment with dolutegravir was not associated with improvement in clinical recovery. Larger randomized trials are required to provide more robust evidence about the effectiveness of dolutegravir.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"29952"},"PeriodicalIF":2.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of key pathways and molecular players potentially involved in endometrial cancer metastasis through integrated bioinformatics analyses.","authors":"Maryam Rezazadeh, Shahla Danaei-Mehrabad, Nahideh Afshar Zakariya, Fatemeh Kazemi, Marziyeh Sadat Moslehian, Amin Tamadon, Reza Shirazi, Mahdi Mahdipour, Parvin Hakimi","doi":"10.34172/bi.30222","DOIUrl":"10.34172/bi.30222","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Endometrial cancer (EC) is a particularly frequent gynecological cancer, and metastasis is the leading cause of death in patients with EC. Using publicly accessible gene expression data, a bioinformatics study was carried out to increase our knowledge and reveal treatment targets for EC metastasis. This study aimed to identify new important molecular actors and clarify the molecular processes and pathways underlying EC metastasis.</p><p><strong>Methods: </strong>The GEOexplorer and R programming languages were used to analyze and visualize gene expression data from EC metastatic gene expression datasets, and differentially expressed genes (DEGs) and differentially expressed lncRNAs (DElncRNAs) were identified using bioinformatics with P-value thresholds of < 0.05, and |log2FC| > 1.5. KEGG pathway enrichment analysis and gene ontology enrichment was used to enrich the observed DEGs, protein-protein interactions were established, and hub genes were identified.</p><p><strong>Results: </strong>The findings revealed that DEGs were considerably enriched in a number of pathways, including the \"Pathways in cancer\", \"Breast cancer\", and \"<i>Rap1</i> signaling pathway.\" DEGs were also found to be involved in a number of biological processes, cellular components, and molecular activities. The PPI network included the hub genes <i>CTNNB1</i>, <i>FGFR3</i>, <i>ESR1</i>, and <i>SRSF3</i> as well as a number of DElncRNAs, such as <i>LINC01541, SNHG17, LINC00520, BHLHE22-AS1, LOC100509445, H19</i>, and <i>HOTAIRM1</i>.</p><p><strong>Conclusion: </strong>This study contributes to our understanding of the molecular processes driving EC metastasis, which may result in the development of new treatment targets and indicators for the early identification of EC metastasis. More studies are needed to validate these findings and to understand the functional roles of these key factors in EC metastasis.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30222"},"PeriodicalIF":2.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}